Avani Amin

Avani Amin practices at UPMC Passavant-McCandless in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Avani Amin's NPI, 1609300862, was assigned on April 14, 2017. Avani Amin graduated from Temple University School of Medicine in 2017. Avani Amin holds Maryland license D91185.

Avani Amin's primary practice is UPMC Passavant-McCandless, at 9100 Babcock Boulevard, Pittsburgh, PA 15237 in Allegheny County. The practice phone is (412) 367-6700.

Avani Amin's primary practice is UPMC Passavant-McCandless in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Avani Amin is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Avani Amin to 4 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Avani Amin practices, 3 sites in all. Vendor and product names are available with a free account.

Hospitalist is Avani Amin's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Avani Amin is licensed in Maryland.

CMS data shows 308 Medicare services from Avani Amin across 6 procedure codes in 2024, for 159 Medicare patients. Medicare paid $25,500 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 159 Medicare patients who saw Avani Amin in 2024. The largest group is 75 to 84, with 54 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Avani Amin's median patient age at 72, with 47% women.

In 2024, Avani Amin wrote 148 Medicare Part D claims for 75 patients. 89% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $53 in total drug cost. In 2023, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Avani Amin for performance year 2024, reported as part of a group. Avani Amin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 4 general payments to Avani Amin from 2 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $55.

Avani Amin graduated from Temple University School of Medicine in 2017.